CT

 

Hosted by      NDA

CLINICAL TRIAL OF THE YEAR


This award recognises a European life science company that has realised a significant milestone in the clinic for a new therapy, drug, diagnostic tool, digital application or medical device.

Qualifying criteria

- Open to private or public biotech companies with a market cap of less than $10bn
- Clinical breakthrough to have been achieved in the period between 1 September 2018 and 1 September 2019

Judges will be paying particular attention to:

- Targeting of unmet medical need
- Key indicators / results / inflection points of clinical development
- Phase / speed / progress through clinical stage
- Innovative trial design / patient centric approach
- Outline of future timelines / value creation
 
 
2019 WINNER
 
 
 
 
 
 
(L-R) Johan Stromquist, CEO, NDA Group, Onno van de Stolpe, CEO, Galapagos, ofie van Gijsel, Galapagos, Maria Nichol, VP, Intellectual Property, Galapagos, and Ellie Taylor, Emcee,
 
 
 
2019 HIGHLY COMMENDED
 
 
 
 

2019 FINALISTS

 

Alkermes

ALKERMES PLC, ALKS 3831, ENLIGHTEN-2, PHASE III

Antipsychotic for the treatment of Schizophrenia
Galapagos

GALÁPAGOS, FINCH 1 AND 3, PHASE III

Methotrexate-Naïve Rheumatoid Arthritis
Imcyse

IMCYSE, IMCY-0098, PHASE IB

Treatment of Type 1 Diabetes
Novaliq

NOVALIQ GMBH, SEECASE NOV03, PHASE II

Treatment of Dry Eye Disease (DED)
Rexgenero

REXGENERO, REX-001, PHASE III

Ischemic Ulcer Immunotherapy

BUY TICKETS AND TABLES